IKZF Family Degrader

IKZF Family Degraders (33):

Cat. No.	Product Name	Effect	Purity

HY-122542B

PPACK TFA	Degrader	99.80%
PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1.

HY-144841

Cemsidomide	Degrader	99.54%
Cemsidomide (CFT7455) is a ubiquitin ligase pathway based IKZF1/3 (Ikaros/Aiolos) degrader with molecular glue activity. Cemsidomide has a GI₅₀ of 0.05 nM for NCIH929.1 cells. Cemsidomide is used in the research of multiple myeloma (MM).

HY-157334

DEG-77	Degrader	99.03%
DEG-77 is a molecular glue targeting IKZF2 and CK1α, with DC₅₀ values of 15.3 nM and 10 nM, respectively. DEG-77 exhibits significant anti-tumor activity, inducing increased transcriptional levels of the pro-apoptotic protein Bax and the cell cycle arrest protein p21. DEG-77 is applicable to the research of acute myeloid leukemia (AmL), diffuse large B-cell lymphoma and ovarian cancer.

HY-182467

BMS-986482	Degrader
BMS-986482 is a CELMoD, CRBN-mediated, selective IKZF1-4 Molecular Glue degrader. The activity of BMS-986482 is driven by a non-traditional CELMoD core that selectively degrades the IKZF protein family. BMS-986482 inhibits tumor growth in preclinical mouse models. BMS-986482 can be used for the research of advanced solid tumors. .

HY-159647

PLX-4545	Degrader
PLX-4545 is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PLX-4545 binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8⁺ T cell responses, and modulates the T_eff:T_reg balance. PLX-4545 also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PLX-4545 can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1.

HY-122542A

PPACK dihydrochloride	Degrader	99.07%
PPACK dihydrochloride is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK dihydrochloride binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK dihydrochloride also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK dihydrochloride can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1.

HY-159647A

(S,S)-PLX-4545	Degrader
(S,S)-PLX-4545 (Compound I) is an orally active and cereblon-based molecular glue degrader of IKZF2 (zinc finger transcription factor Helios). (S,S)-PLX-4545 can be used for the study of IKZF2-mediated diseases or disorders, such as proliferative diseases or disorders and/or cancer.

HY-172931

DEG-35	Degrader	98.88%
DEG-35 is a CRBN-dependent, dual IKZF2 and CK1α molecule glue degrader, with DC₅₀ values of 1.4 nM and 4.4 nM for CK1α and IKZF2, respectively. DEG-35 activates the p53 apoptosis pathway. DEG-35 can be used in the research for Acute Myeloid Leukemia (AML).

HY-168615

MGD-28	Degrader	99.73%
MGD-28 is a potent, orally active, Cereblon (CRBN)-dependent IKAROS protein degrader that degrades IKZF1 (DC₅₀=3.8 nM), IKZF2 (DC₅₀=56.3 nM), and IKZF3 (DC₅₀=7.1 nM) in a dose-dependent manner. In addition, MGD-4 also degrades CK1α (DC₅₀=7.8 nM). MGD-28 has antiproliferative activity and can be used in multiple myeloma research.

HY-172930

PVTX-405	Degrader
PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC₅₀ of 0.7 nM and a D_max of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC₅₀ of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn^391V C57BL/6 mice.

HY-159647B

(1S,2S,3R)-PLX-4545	Degrader
(1S,2S,3R)-PLX-4545 is the (1S,2S,3R) enantiomer of PLX-4545 (HY-159647). PLX-4545 is an orally active and selective cereblon-based molecular glue degrader of IKZF2 (zinc finger transcription factor Helios). PLX-4545 can reprogram immunosuppressive regulatory T cells into pro-inflammatory effector T cells, thereby enhancing anti-tumor immune responses.

HY-Y1863

3-Chlorobenzaldehyde	Degrader	99.58%
3-Chlorobenzaldehyde (m-Chlorobenzenecarboxaldehyde) is a kind of biological materials or organic compounds that are widely used in life science research.

HY-168614

MGD-4	Degrader
MGD-4 is an orally active, Cereblon (CRBN)-dependent IKAROS protein degrader that degrades IKZF1 (DC₅₀=67.2 nM), IKZF2 (DC₅₀=918.2 nM), and IKZF3 (DC₅₀=95.8 nM) in a dose-dependent manner. MGD-4 effectively inhibits the growth of multiple myeloma.

HY-179075

PROTAC BCL6/IKZF1/3 Degrader-1	Degrader
PROTAC BCL6/IKZF1/3 Degrader-1 is a selective and orally active BCL6 and IKZF1/3 PROTAC degrader. PROTAC BCL6/IKZF1/3 Degrader-1 exhibits superior antiproliferative effects in various germinal center B-cell-like (GCB) and activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) cell lines. PROTAC BCL6/IKZF1/3 Degrader-1 can be used for the research of cancer, such as lymphoma. (Structure Note: Pink: BCL6/IKZF1/3 ligand (HY-179064); Blue: CRBN ligand (HY-41547); Black: linker (HY-42427); CRBN ligand-Linker: (HY-179066))

HY-177754

IKZF2-degrader 3	Degrader
IKZF2-degrader 3 (compound 6) is a molecular glue IKZF2 degrader with a DC₅₀ of 2.0 nM.

HY-182799

IBA-12	Degrader
IBA-12 is a IKZF2 molecular glue/PROTAC degrader with a DC₅₀ of 276.2 nM (Jurkat cells) and 461.8 nM (Mino cells), and an IC₅₀ of 179.9 nM. IBA-12 binds to the canonical tryptophan triad pocket of CRBN to form a ternary complex with IKZF2. IBA-12 induces IKZF2 degradation mediated by the CRBN-dependent ubiquitin-proteasome system, with no effect on other CRBN substrates. IBA-12 induces the production of interleukin-2 (IL-2) through degrading IKZF2. IBA-12 is applicable to cancer immunology research.

HY-169077

IKZF3 degrader 1	Degrader
IKZF3 degrader 1 (compound 19a) is a molecular glue degrader of IKZF3 (EC₅₀=0.012 μM). IKZF3 degrader 1 promotes the binding of IKZF3 to Cereblon (CRBN), leading to the ubiquitination and degradation of IKZF3.

HY-175601

DD-04-038	Degrader
DD-04-038 is a molecular glue degrader. DD-04-038 induces proteins (such as IKZF1/3, ZBED3 and PATZ1) to bind to CRBN, promoting their ubiquitination and degradation.

HY-180836

DIX-01	Degrader
DIX-01 is a molecular gel degrader that can simultaneously induce the degradation of IKZF1/3 and GSPT1 mediated by CRBN. Its DC₅₀ values are: IKZF1 (19.80 nM), IKZF3 (45.31 nM), and GSPT1 (120.1 nM). DIX-01 exhibits nanomolar-level potent anti-proliferative activity in various cancer cell lines. DIX-01 induces apoptosis in MV4-11 cells and significantly inhibits the growth of leukemia cells in zebrafish. DIX-01 can be used for the study of malignant hematological tumors.

HY-175502

MGD-22	Degrader
MGD-22, a molecular glue, is an orally active IKZF1/2/3 degrader with DC₅₀ values of 8.33 nM, 9.91 nM, and 5.74 nM, respectively. MGD-22 exhibits extremely potent anti-proliferative activity against diverse hematological cancer cells. MGD-22 induces apoptosis in cancer cells. MGD-22 demonstrates potent anti-tumor efficacy in mice bearing NCI-H929 xenografts or WSU-DLCL-2 xenografts. MGD-22 can be used for the study of hematological cancers, including multiple myeloma (MM), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL).

Name
Email *

	Sorry, but the email address you supplied was invalid.